Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742959 · ClinicalTrials.gov registry record · Phase 1
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by TransThera Sciences (Nanjing).
- Completed
- Registry status
- Phase 1
- Development phase
- 203
- Enrollment target
NCT04742959: Completed Phase 1 study, sponsored by TransThera Sciences (Nanjing).
NCT04742959 is a Phase 1 study that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 203 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04742959, a Phase 1 study, has completed, sponsored by TransThera Sciences (Nanjing).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 203 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
Primary Outcome
As assessed per NCI Common Toxicity Criteria for Adverse Events, version 5.0
Interventions
- DRUG TT-00420
- COMBINATION_PRODUCT Nab-Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2021-03-14 |
| Est. Completion | 2024-02-20 |
| Phase | Phase 1 |
What the finished NCT04742959 record still lists
NCT04742959 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 2 interventions - of which TT-00420 is the first listed.
NCT04742959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04742959 about?
NCT04742959 is a clinical study titled "Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors". This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
What is the current status of trial NCT04742959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 203 participants. The study started on 2021-03-14. Estimated completion is 2024-02-20.
What interventions are being tested in trial NCT04742959?
The interventions under investigation include: TT-00420 (DRUG), Nab-Paclitaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04742959?
This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04742959's enrollment target sits among peer trials
203 258th of 2000 higher than 1,743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI